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Where do we go from here? The inexorable use of TAVR in lower risk patients will continue. As lower risk patients are treated, the impact of residual aortic insufficiency, the need for a permanent pacemaker, and valve durability will be of increasing importance.
Counterbalancing these potential limitations of TAVR are progressive enhancements in valve technology and procedural simplicity (17) . 
